Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: A meta-analysis

Canadian Journal of Psychiatry

Volumn 55, Issue 2, 2010, Pages 91-99

  Dowlati, Yekta ^a,b   Herrmann, Nathan ^a,b   Swardfager, Walter L ^a,b   Reim, Elyse K ^b   Lanctôt, Krista L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Antidepressant; Coronary artery disease; Depression

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIRTAZAPINE; PLACEBO; SERTRALINE;

ADVERSE OUTCOME; BECK DEPRESSION INVENTORY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; META ANALYSIS; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77649247038     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005500205     Document Type: Review

References (87)

1. Frasure-Smith N, Koszycki D, Swenson JR, et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosom Med. 2006;68(1):87-93.
2. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55(7):580 -592.
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
4. Rice DP, Miller LS. The economic burden of affective disorders. Br J Psychiatry. 1995(27):34 -42.
5. Angst J. Epidemiology of depression. Psychopharmacology. 1992;106:S71-S74.
6. Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001;62(Suppl 26):5-9.
7. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med. 1996;58(2):99-110.
8. Ladwig KH, Kieser M, Konig J, et al. Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J. 1991;12(9):959-964.
9. Lesperance F, Frasure-Smith N. Depression and coronary artery disease: time to move from observation to trials. CMAJ. 2003;168(5):570 -571.
10. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993;270(15):1819-1825.
11. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91(4):999-1005.
12. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149(8):1785-1789.
13. Carney RM, Rich MW, Tevelde A, et al. Major depressive disorder in coronary artery disease. Am J Cardiol. 1987;60(16):1273-1275.
14. Burg MM, Abrams D. Depression in chronic medical illness: the case of coronary heart disease. J Clin Psychol. 2001;57(11):1323-1337.
15. Strik JJ, Lousberg R, Cheriex EC, et al. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. J Psychosom Res. 2004;56(1):59-66.
16. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66(6):814-822.
17. Ahern DK, Gorkin L, Anderson JL, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol. 1990;66(1):59-62.
18. Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet. 2003;362(9384):604-609.
19. Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol. 1995;14(5):388-398.
20. Friedmann E, Thomas SA, Liu F, et al. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J. 2006;152(5):940.e1-940.e8
21. Januzzi JL Jr, Stern TA, Pasternak RC, et al. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med. 2000;160(13):1913-1921.
22. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000;48(4-5):379-391.
23. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349(9063):1436- 1442.
24. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58(3):221-227.
25. Ruo B, Rumsfeld JS, Hlatky MA, et al. Depressive symptoms and health-related quality of life: the heart and soul study. JAMA. 2003;290(2):215-221.
26. Stern MJ, Pascale L, Ackerman A. Life adjustment postmyocardial infarction: determining predictive variables. Arch Intern Med. 1977;137(12):1680-1685.
27. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systoloc Hypertension in the elderly). Arch Intern Med. 1996;156(5):553-561.
28. de Jonge P, Spijkerman TA, van den Brink RH, et al. Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart. 2006;92(1):32-39. Epub 2005 May 12.
29. Ellis JJ, Eagle KA, Kline-Rogers EM, et al. Depressive symptoms and treatment after acute coronary syndrome. Int J Cardiol. 2005;99(3):443-447.
30. Swardfager W, Herrmann N, Dowlati Y, et al. Relationship between cardiopulmonary fitness and depressive symptoms in cardiac rehabilitation patients with coronary artery disease. J Rehabil Med. 2008;40(3):213-218.
31. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66(6):802-813.
32. Statistics Canada. Causes of death 2002 [Internet]. Ottawa (ON): Statistics Canada; 2004 [cited 2009 Nov 25]. Available from: http://www.statcan.gc.ca/pub/84-208-x/84-208-x2004002-eng.htm.
33. Faris R, Purcell H, Henein MY, et al. Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. Eur J Heart Fail. 2002;4(4):541-551.
34. Parissis JT, Fountoulaki K, Filippatos G, et al. Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic implications. Int J Cardiol. 2007;116(2):153-160.
35. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709.
36. Swenson JR, O'Connor CM, Barton D, et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol. 2003;92(11):1271-1276.
37. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367-379.
38. Honig A, Kuyper AM, Schene AH, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606-613.
39. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62(6):783-789.
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): APA; 2000.
41. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896-1900.
42. Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232-236.
43. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609-613.
44. Jadad AR, Moore RA, Carroll D, et al. Assesing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
45. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
46. Beck AT. Psychometric properties of the Beck Depression Inventory: twenty-five years later. Clin Psychol Rev. 1988;8:77-100.
47. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
48. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
49. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
50. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454.
51. Alves TC, Rays J, Telles RM, et al. Effects of antidepressant treatment on cognitive performance in elderly subjects with heart failure and comorbid major depression: an exploratory study. Psychosomatics. 2007;48(1):22-30.
52. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003;289(23):3106-3116.
53. Chazov EI, Oganov RG, Pogosova GV, et al. [Depression in cardiological practice: pilot results from a multicenter clinico-epidemiological trial in hypertensive patients with ischemic heart disease (koordinata)]. Ter Arkh. 2006;78(4):38-44.
54. Glassman AH, Bigger JT, Gaffney M, et al. Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry. 2006;63(3):283-288.
55. Glassman AH, Bigger JT, Gaffney M, et al. Heart rate variability in acute coronary syndrome patients with major depression: influence of sertraline and mood improvement. Arch Gen Psychiatry. 2007;64(9):1025-1031.
56. Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J. 2007;153(5):868-873.
57. Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165(21):2497-2503.
58. Koszycki D, Lafontaine S, Frasure-Smith N, et al. An open-label trial of interpersonal psychotherapy in depressed patients with coronary disease. Psychosomatics. 2004;45(4):319-324.
59. McFarlane A, Kamath MV, Fallen EL, et al. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J. 2001;142(4):617-623.
60. Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999;156(7):1024-1028.
61. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20(2):137-140.
62. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155(5):660-665.
63. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287-291.
64. Serebruany VL, Glassman AH, Malinin AI, et al. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail. 2003;5(4):517-521.
65. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circulation. 2003;108(8):939-944.
66. Serebruany VL, Suckow RF, Cooper TB, et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry. 2005;162(6):1165-1170.
67. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-798.
68. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460-466.
69. Van Zyl LT, Lesperance F, Frasure-Smith N, et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis. 2009;27(1):48-56.
70. Xiong GL, Jiang W, Clare R, et al. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol. 2006;98(1):42-47.
71. Zeng W, Ma H, Liang Q, et al. [The influence of antidepressive therapy on short-term prognosis in elderly patients with unstable angina and depression]. Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine]. 2001;40(12):809-810.
72. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev. 2000;(4):CD001312.
73. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13(2):100-108.
74. De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence. Drug Saf. 2003;26(1):55-64.
75. Muijsers RB, Plosker GL, Noble S. Spotlight on sertraline in the management of major depressive disorder in elderly patients. CNS Drugs. 2002;16(11):789-794.
76. Shapiro PA, Lesperance F, Frasure-Smith N, et al. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J. 1999;137(6):1100-1106.
77. Sheikh JI, Cassidy EL, Doraiswamy PM, et al. Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc. 2004;52(1):86-92.
78. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev. 2007;(1):CD004364.
79. Furukawa TA, Watanabe N, Omori IM, et al. Can pill placebo augment cognitive-behavior therapy for panic disorder? BMC Psychiatry. 2007;7:73.
80. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20(6):449-458.
81. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(4):CD005454.
82. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Eng J Med. 2008;358(3):252-260.
83. National Institute of Clinical Excellence. Guidelines on Depression: London (GB): Department of Health; 2004.
84. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
85. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300(18):2161- 2171.
86. Thase ME, Kennedy SH. Assessing the true treatment effect of active treatment vs placebo therapy in patients with severe MDD. American Psychiatric Association 161st Annual Meeting; 2008; Washington (DC).
87. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768-1775.